	US 12,251,410 B2
	Anticancer trail-targeted plant virus particles
Nicole F. Steinmetz, San Diego, CA (US)
Assigned to CASE WESTERN RESERVE UNIVERSITY, Cleveland, OH (US)
Filed by CASE WESTERN RESERVE UNIVERSITY, Cleveland, OH (US)
Filed on Jun. 13, 2023, as Appl. No. 18/209,138.
Application 18/209,138 is a continuation of application No. 16/614,676, granted, now 11,672,840, previously published as PCT/US2018/033203, filed on May 17, 2018.
Claims priority of provisional application 62/507,603, filed on May 17, 2017.
Prior Publication US 2024/0115635 A1, Apr. 11, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/76 (2015.01); A61K 31/282 (2006.01); A61K 31/436 (2006.01); A61K 38/17 (2006.01); A61K 47/69 (2017.01); A61P 35/04 (2006.01); C12N 7/00 (2006.01)

CPC A61K 35/76 (2013.01) [A61K 31/282 (2013.01); A61K 31/436 (2013.01); A61K 38/1793 (2013.01); A61K 47/6901 (2017.08); A61P 35/04 (2018.01); C12N 7/00 (2013.01)]

17 Claims

1. A method of treating tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-sensitive cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an agent comprising a potato virus X (PVX) plant virus particle or virus-like particle (VLP) which is non-covalently conjugated via a nickel-coordinated nitrilotriacetic acid (Ni-NTA) module to at least one TRAIL by coordination bonds between the Ni-NTA modules displayed on the PVX plant virus particle or VLP outer surface and a histidine-tag on TRAIL.